首页> 外文OA文献 >A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC)

【2h】

A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC)

机译：在预处理HER2 +不可切除的局部晚期或转移性乳腺癌（MBC）中，在患有预处理HER2 +不可切除的乳腺癌（MBC）的患者中，对ONT-380与Capecitabine（C）和曲妥珠单抗（T）组合的A组随机，双盲，对照研究。

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
G. Curigliano; S. Loibl; V. Müller; X. Pivot; A. Wardley; D. Cameron;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. 来自一项艾日布林联合吉西他滨对比紫杉醇联合吉西他滨作为HER2阴性转移性乳腺癌的一线化疗的II期、多中心、随机试验的包含神经病变相关量表的生活质量结果:韩国癌症研究组试验(KCSG BR13-11) [J] . Ji-Yeon Kim, Young-Hyuck Im, Tae-Yong Kim, 癌症（英文版） . 2019,第008期
2. A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial [J] . José Baselga, Frederico Costa, Henry Gomez, Trials . 2013,第1期

机译：比较卡培他滨E与索拉非单抗或pLacebo联合治疗局部晚期或转移性HER2阴性乳腺癌CancEr的3期试验（RESILIENCE研究）：一项随机对照试验的研究方案
3. Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial. [J] . Hamberg P, Bos MM, Braun HJ, Clinical breast cancer . 2011,第2期

机译：II期随机研究比较了曲妥珠单抗和多西他赛联合治疗与序贯治疗的曲妥珠单抗联合多西他赛在HER2 +转移性乳腺癌患者一线化疗中的疗效和安全性：HERTAX试验。
4. BOLERO-1: A Randomized, Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Everolimus in Combination With Trastuzumab and Paclitaxel as First-Line Therapy in Women With HER2-Positive (HER2 + ), Locally Advanced or Metastatic Breast Cancer (BC) [J] . Clinical advances in hematology & oncology: H&O . 2012,第Suppla14期

机译：BOLERO-1：依维莫司联合曲妥珠单抗和紫杉醇作为一线治疗对HER2阳性（HER2 +），局部晚期或转移性乳腺癌的女性进行的随机，III期，双盲，安慰剂对照的依维莫司多中心试验公元前）
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial [O] . José Baselga, Frederico Costa, Henry Gomez, 2013

机译：第3阶段比较卡培他滨E与SorafenIb或pLacebo联合治疗局部晚期或转移性HER2阴性乳腺癌CancEr（RESILIENCE研究）：一项随机对照试验的研究方案
7. A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial [O] . José Baselga, Frederico Costa, Henry Gomez, 2013

机译：第3阶段比较卡培他滨E与SorafenIb或pLacebo联合治疗局部晚期或转移性HER2阴性乳腺癌CancEr（RESILIENCE研究）：一项随机对照试验的研究方案

A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC)

著录项

相似文献

相关主题

期刊订阅